Aisa Pharma is focused on developing a novel treatment for the pressing medical needs of patients with Systemic Sclerosis (or Scleroderma) who demonstrate Raynaud’s Phenomenon. Preliminary clinical data is encouraging and implies treatment effects of our drug on both Raynaud’s and aspects of the underlying disease and associated symptoms.
About AISA Pharma
AISA Pharma is a late-stage, clinical development company dedicated to bringing new treatments to patients with severe autoimmune and vascular diseases.
About AISA-021
AISA-021 is being developed to treat Systemic Sclerosis and the Raynaud’s Phenomenon that affects 95% of patients with the disease.
Our Team
The people at AISA Pharma have over 100 years of experience in bringing new drugs to market. We also have a seasoned executive and advisory board of well-known biopharma experts.
Contact Us
Keep in touch! Submit a question or subscribe to our mailing list. AISA Pharma is located in Boston with offices in California and Australia. Investor information is available.
Raynaud syndrome, also known as Raynaud’s phenomenon, is a medical condition in which the spasm of small arteries causes episodes of reduced blood flow to end arterioles. Typically the disease occurs in the fingers, and less commonly, the toes and other extremities. The episodes classically result in the affected part turning white, blue, then red. Although usually self-limited, severe recurrent episodes can result in gangrene and amputation.